An update on the clinical use of methadone for cancer pain

Pain

Volumn 70, Issue 2-3, 1997, Pages 109-115

  Ripamonti, Carla ^a   Zecca, Ernesto ^a   Bruera, Eduardo ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

cancer pain; equianalgesia; methadone; oral and rectal route

Indexed keywords

HYDROMORPHONE; METHADONE;

ANALGESIA; CANCER PAIN; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; REVIEW; SEDATION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030928512     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(96)03286-1     Document Type: Review

References (69)

1. Abramson, F.P., Methadone plasma protein binding: alterations in cancer and displacement from alpha-1-acid glycoprotein, Clin. Pharmacol. Ther., 32 (1982) 652-658.
2. Agency for Health Care Policy Research, Management of Cancer Pain, Clinical Practice Guidelines, Rockville, MD, US Department of Health and Human Services, AHCPR Publications N. 94-0592, March 1994.
3. Atkinson, A., Addictive treatment, Nurs. Times, 84 (1988) 42-47.
4. Babul, N. and Darke, A.C., Putative role of hydromorphone metabolites in myoclonus, Pain, 51 (1992) 260-261.
5. Baumann, P., Tinguely, D. and Schopf, J., Increase of alpha-1-acid glycoprotein after treatment with amitriptyline, Br. J. Clin. Pharmacol., 14 (1982) 102-103.
6. Beaver, W.T., Wallenstein, S.L., Houde, R.W. and Rogers, A., A clinical comparison of the analgesic effects of methadone and morphine administered intramuscularly and of orally and parenterally administered methadone, Clin. Pharmacol. Ther., 8 (1967) 415-426.
7. Bruera, E., Watanabe, S., Fainsinger, R.L. et al., Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain, Pain, 62 (1995a) 141-146.
8. Bruera, E., Franco, J.J., Maltoni, M., Watanabe, S. and Suarez-Almazor, M., Changing pattern of agitated impaired mental status in patients with advanced cancer: association with cognitive monitoring, hydration, and opioid rotation, J. Pain Symptom Manage., 10 (1995b) 287-291.
9. Bruera, E., Pereira, J., Watanabe, S., Belzile, M., Kuehn, N. and Hanson, J., Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone and morphine, Cancer, 78 (1996a) 852-857.
10. Bruera, E., Belzile, M., Watanabe, S. and Fainsinger, R.L., Volume of hydration in terminal cancer patients, Support Care Cancer, 4 (1996b) 147-150.
11. Crews, J.C., Sweeney, N.J. and Denson, D.D., Clinical efficacy of methadone in patients refractory to other mu-opioid receptor agonist analgesics for management of terminal cancer pain, Cancer, 72 (1993) 2266-2272.
12. De Conno, F., Ripamonti, C., Saita, L., MacEachern, T., Hanson, J. and Bruera, E., Role of rectal route in treating cancer pain: a randomized crossover clinical trial of oral versus rectal morphine administration in opioid-naive cancer patients with pain, J. Clin. Oncol., 13 (1995) 1004-1008.
13. De Conno, F., Groff, L., Brunelli, C., Zecca, E., Ventafridda, V. and Ripamonti, C., Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients, J. Clin. Oncol., 14 (1996) 2836-2842.
14. de Stoutz, N.D., Bruera, E. and Suarez-Almazor, M., Opioid rotation for toxicity reduction in terminal cancer patients, J. Pain Symptom Manage., 10 (1995) 378-384.
15. Dole, V.P. and Kreek, M.J., Methadone plasma level: sustained by a reservoir of drug in the tissue, Proc. Natl. Acad. USA, 70 (1973) 10.
16. Fainsinger, R., Schoeller, T. and Bruera, E., Methadone in the management of cancer pain: a review, Pain, 52 (1993) 137-147.
17. Galer, B.S., Coyle, N. and Pasternak, G.W. et al., Individual variability in the response to different opioids: report of five cases, Pain, 49 (1992) 87-91.
18. Gardner-Nix, I.S., Oral methadone for managing chronic non-malignant pain, J. Pain Symptom Manage., 11 (1996) 321-328.
19. Glare, P.A., Walsh, T.D. and Pippenger, C.E., Normorphine, a neurotoxic metabolite, Lancet, 335 (1990) 725-726.
20. Gorman, E.S. and Warfield, C.A., The use of opioids in the management of pain, Hosp. Pract., 12 (1986) 48A-H.
21. Gourlay, G.K., Cherry, D.A. and Cousin, M.J., A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer, Pain, 25 (1986) 297-312.
22. Hagen, N.A., Foley, K.M., Cerbone, D.J. et al., Chronic nausea and morphine-6-glucuronide, J. Pain Symptom Manage., 6 (1991) 125-128.
23. Hagen, N., Thirlwell, M., Dhaliwal, H.S., Babul, N., Harsanyi, Z. and Darke, A.C., Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone, J. Clin. Pharmacol., 35 (1995) 37-44.
24. Health and Welfare Canada, Cancer pain: a monograph on the management of cancer pain, Ottawa, Health and Welfare Canada, Minister of Supply and Services, Canada, H422/5, 1984E.
25. Henderson, G.L., Frincke, J.M., Garber, R.J. and Knight, H.J., Metabolism and disposition of fentanyl in man and the horse, Proc. West. Pharmacol. Soc., 24 (1981) 137-140.
26. Hill, C.S., Oral opioid analgesics. In: R.B. Patt (Ed.), Cancer Pain, J.B. Lippincott, Philadelphia, 1993, pp. 129-142.
27. Hochman, M.S., Meperidine-associated myoclonus and seizures in long-term hemodialysis patients, Ann. Neurol., 14 (5) (1983) 257-260.
28. Houde, R.E., Misinformation: side-effects and drug interactions. In: C.S. Hill and W.S. Fields (Eds.), Advances in Pain Research and Therapy, Raven Press, New York, 1989, pp. 145-161.
29. Hunt, G. and Bruera, E., Respiratory depression in a patient receiving oral methadone for cancer pain, J. Pain Symptom Manage., 10 (1995) 401-404.
30. Inturrisi, C.E., Colburn, W.A., Kaiko, R.F. et al., Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain, Clin. Pharmacol. Ther., 41 (1987) 392-401.
31. Inturrisi, C.E., Portenoy, R.K., Max, M.B. et al., Pharmacokinetic-pharmacodynamic relationships of methadone infusions in patients with cancer pain, Clin. Pharmacol. Ther., 47 (1990) 565-577.
32. Inturrisi, C.E. and Hanks, G.W.C., Opioid analgesic therapy. In: D. Doyle, G.W.C. Hanks and N. MacDonald (Eds.), Oxford Textbook of Palliative Medicine, Oxford Medical Publications, Oxford University Press, Oxford, 1993, pp. 166-182.
33. Ivarsson, M. and Neil, A., Differences in efficacies between morphine and methadone demonstrated in the guinea pig ileum: a possible explanation for previous observations on incomplete opioid cross-tolerance, Pharmacol. Toxicol., 65 (1989) 368-371.
34. Kaiko, R.F., Foley, K.M., Grabinski, P.Y. et al., Central nervous system excitatory effects of meperidine in cancer patients, Ann. Neurol., 13 (1983) 180-185.
35. Kolassa, M., Guidance for clinicians in discerning and comparing the price of pharmaceutical agents, J. Pain Symptom Manage., 9 (1994) 235-243.
36. Kreek, M.J., Garfield, J.W. and Giusti, L.M., Rifampicin-induced methadone withdrawal, N. Engl. J. Med., 294 (1976) 1104-1106.
37. Levy, M., Pain management in advanced cancer, Sem. Oncol., 12 (4) (1985) 394-410.
38. MacDonald, N., Der, L., Allan, S. and Champion, P., Opioid hypexcitability: the application of alternate opioid therapy, Pain, 53 (1993) 353-355.
39. Mercadante, S., Sapio, M., Serretta, R. and Caligara, M., Patient-controlled analgesia with oral methadone in cancer pain, Ann. Oncol., 7 (1996) 613-617.
40. Morley, J.S., Watt, J.W.G., Wells, J.C. et al., Methadone in pain uncontrolled by morphine, Lancet, 342 (1993) 1243.
41. Neil, A., Morphine- and methadone-tolerant mice differ in cross-tolerance to other opiates, Naunyn Schmiedeberg's Arch. Pharmacol., 320 (1982) 50-53.
42. Nilsson, M.I., Meresaar, U., Anggard E. et al., Clinical pharmacokinetics of methadone, Acta Anaesth. Scand., S74 (1982a) 66-69.
43. Nilsson, M.I., Widelov, E., Meresaar, U. et al., Effect of urinary pH on the disposition of methadone in man, Eur. J. Clin. Pharmacol., 22 (1982b) 337-342.
44. Paalzow, L., Nilsson, L., Stenberg, P. et al., Pharmacokinetic basis for optimal methadone treatment of pain in cancer patients, Acta Anaesth. Scand., S74 (1982a) 55-58.
45. Paalzow, L., Pharmacokinetic aspects of optimal pain treatment, Acta Anaesth. Scand., S74 (1982b) 37-39.
46. Plummer, J.L., Gourlay, G.K., Cherry, D.A. et al., Estimation of methadone clearance: application in the management of cancer pain, Pain, 33 (1988) 313-322.
47. Portenoy, R.K., Foley, K.M., Stulman, J. et al., Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steadystate concentrations and the consequences of renal failure, Pain, 47 (1991) 13-19.
48. Rane, A., Sawe, J., Dahlstrom, B. et al., Pharmacological treatment of cancer pain with special reference to the oral use of morphine, Acta Anaesth. Scand., S76 (1982) 97-99.
49. Rimmer, T. and Trotman, I., Methadone restores opioid sensitivity in cancer pain (abstract), Palliative Med., 10 (1996) 58.
50. Ripamonti, C., and Bruera, E., Rectal, buccal, and sublingual narcotics for the management of cancer pain, J. Palliative Care, 7 (1) (1991) 30-35.
51. Ripamonti, C., Zecca, E., Brunelli, C. et al., Rectal methadone in cancer patients with pain. A preliminary clinical and pharmacokinetic study, Ann. Oncol., 6 (1995) 841-843.
52. Ripamonti, C. and Bruera, E., Guidelines for the drug treatment of CNS adverse effect of opioids, CNS Drugs, (1996) in press.
53. Rogers, A.G., The use of methadone in opioid-tolerant patients, J. Pain Symptom Manage., 3 (1988) 45.
54. Romach, M.K., Piafsky, K.M., Abel, J.G. et al., Methadone binding to orosomucoid (alpha-1-acid-glycoprotein) determinant of free fraction in plasma, Clin. Pharmacol. Ther., 29 (1981) 211-217.
55. Sawe, J., High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment, Clin. Pharmacokinetics, 11 (1986) 87-106.
56. Sawe, J., Dahlstrom, B., Paalzow, L. et al., Morphine kinetics in cancer patients, Clin. Pharmacol. Ther., 30 (1981a) 629-635.
57. Sawe, J., Hansen, J., Ginman, C. et al., Patient-controlled dose regimen of methadone for chronic cancer pain, Br. Med. J., 282 (1981b) 771-773.
58. Schneider, E. and Brune, K., Opioid activity and distribution of fentanyl metabolites, Naunyn Schmiedeberg's Arch. Pharmacol., 334 (1986) 267-274.
59. Silverstein, J.H., Reiders, M.F., McMullin, M., Schulman, S. and Zahl, K., Norfentanyl is detectable in urine for >48 hours; an advance for urine drug testing in anesthesia (abstract), Anesthesiology, 75 (1991) 895.
60. Sjogren, P., Dragsted, L. and Christensen, C.B., Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure, Acta Anaesthesiol. Scand., 37(1993a) 780-782.
61. Sjogren, P., Jonsson, T., Jensen, N.-H., Drenck, N.-E. and Jensen, T.S., Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine, Pain, 55 (1993b) 93-98.
62. Sjogren, P., Jensen, N.-H. and Jensen, T.S., Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists, Pain, 59 (1994) 313-316.
63. Steinberg, R.B., Gilman, D.E. and Johnson, F., Acute toxic delirium in a patient using transdermal fentanyl, Anesth. Analg., 75 (1992) 1014-1016.
64. Szeto, H.H., Inturrisi, C.E., Houde, R. et al., Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure or cancer, Ann. Intern. Med., 86 (1977) 738-740.
65. Thomas, Z. and Bruera, E., Use of methadone in a highly tolerant patient receiving parenteral hydromorphone, J. Pain Symptom Manage., 10 (1995) 315-317.
66. Tong, T.G., Pond, S.M., Kreek, M.J. et al., Phenytoin-induced methadone withdrawal, Ann. Intern. Med., 94 (1981) 349-351.
67. Twycross, R. and Lack, S., Symptom control for advanced cancer, Pain Relief, Pitman Books, London, 1983 pp. 167-189.
68. Ventafridda, V., Ripamonti. C., Bianchi, M. et al., A randomized study on oral administration of morphine and methadone in the treatment of cancer pain, J. Pain Symptom Manage., 1 (1986) 203-207.
69. Vigano, A., Fan, D. and Bruera, E., Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators, Pain, 67 (1996) 115-119.